http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-122917-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 2021-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_caf5e54f7531cdf5a52fd9b2db910ee0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b5efd1cc23ab88099e5fffb7d84f7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce2e08466c124fc43d05498bbdfe4fcf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e179e792aa270498ae9c28633401c62 |
| publicationDate | 2022-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-122917-A1 |
| titleOfInvention | ZIBOTENTAN AND DAPAGLIFLOZIN COMBINATION FOR THE TREATMENT OF ENDOTHELIN-RELATED DISEASES |
| abstract | The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin-related diseases. Claim 1: Zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridin-3-sulfonamide, of formula ( 1), or a pharmaceutically acceptable salt thereof, for use in the treatment of chronic kidney disease in a human patient, zibotentan, or a pharmaceutically acceptable salt thereof, being administered in combination with dapagliflozin, (1S)-1,5- anhydro-1-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol, of formula (2), or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2020-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.